RxDoctor Payments Data

Michael Jackson, MD

Family Medicine · The Woodlands, TXNPI 1124019989

Payments from drug & device makers

$1,231in general payments, 2019–2025

Across 59 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$276
  • Novo Nordisk$268
  • Amgen$135
  • Pfizer$111
  • Lilly USA, LLC$101
  • AbbVie$100
  • plus $240 from 6 others

What the payments were for

  • Food & beverage$1,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,231 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$18,524
Medicare patients
60
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol41$47,636
OzempicSemaglutide22$41,714
JardianceEmpagliflozin25$36,436
EliquisApixaban28$28,431
MounjaroTirzepatide13$12,855
TrulicityDulaglutide12$11,843
MyrbetriqMirabegron11$7,576
Tresiba Flextouch U-100Insulin Degludec14$6,705
Olmesartan Medoxomil38$3,637
Atorvastatin Calcium250$3,085
Ramelteon12$2,260
Ciclopirox15$1,976
Sildenafil Citrate31$1,863
Amlodipine Besylate223$1,774
Nifedipine ErNifedipine53$1,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$276$47,63641 claims
Novo NordiskOzempic$268$41,71422 claims
PfizerEliquis$111$28,43128 claims
Lilly USA, LLCMounjaro, Trulicity$101$24,69825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →